NCT00040521View on ClinicalTrials.gov

Study Evaluating rhIL-11 in Active Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2002

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions
Crohn DiseaseInflammatory Bowel Disease
Interventions
DRUG

Recombinant Human Interleukin-11 (rhIL-11)

Trial Locations (2)

80002

Arvada

27599-7032

Chapel Hill

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00040521 - Study Evaluating rhIL-11 in Active Crohn's Disease | Biotech Hunter | Biotech Hunter